Alpha 2.0
Login Register
» Articles » PMID: 32914220

Letermovir for the Compassionate Therapeutic Use of Cytomegalovirus Infection

Overview
Journal Eur J Clin Microbiol Infect Dis
Publisher Springer
Specialties Infectious Diseases
Microbiology
Date 2020 Sep 11
PMID 32914220
Citations 3
Authors
Lorenz Schubert
Lisa Fisecker
Florian Thalhammer
Heinz Burgmann
Christoph Steininger
Affiliations
Soon will be listed here.
Abstract

Purpose: Data on the efficacy, dosing and safety of letermovir for the compassionate therapeutic use of CMV infections are limited.

Methods: Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections.

Results: Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.7%).

Conclusion: Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.

Citing Articles

New Treatment Options for Refractory/Resistant CMV Infection.

Walti C, Khanna N, Avery R, Helantera I Transpl Int. 2023; 36:11785.

PMID: 37901297 PMC: 10600348. DOI: 10.3389/ti.2023.11785.

Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations.

Polak T, Cucchi D, van Rosmalen J, Uyl-de Groot C, Darrow J Front Pharmacol. 2022; 13:913567.

PMID: 35677436 PMC: 9168458. DOI: 10.3389/fphar.2022.913567.

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients.

Di Cristanziano V, Affeldt P, Trappe M, Wirtz M, Heger E, Knops E Microorganisms. 2021; 9(8).

PMID: 34442744 PMC: 8398864. DOI: 10.3390/microorganisms9081666.

References
1.
Kotton C, Kumar D, Caliendo A, Huprikar S, Chou S, Danziger-Isakov L . The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018; 102(6):900-931. DOI: 10.1097/TP.0000000000002191. View
2.
Lurain N, Chou S . Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010; 23(4):689-712. PMC: 2952978. DOI: 10.1128/CMR.00009-10. View
3.
Marty F, Ljungman P, Chemaly R, Maertens J, Dadwal S, Duarte R . Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017; 377(25):2433-2444. DOI: 10.1056/NEJMoa1706640. View
4.
Ligat G, Cazal R, Hantz S, Alain S . The human cytomegalovirus terminase complex as an antiviral target: a close-up view. FEMS Microbiol Rev. 2018; 42(2):137-145. PMC: 5972660. DOI: 10.1093/femsre/fuy004. View
5.
Kaul D, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P . First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011; 11(5):1079-84. DOI: 10.1111/j.1600-6143.2011.03530.x. View